Evercore ISI Group Maintains Outperform on Krystal Biotech, Raises Price Target to $300

Evercore ISI Group analyst Gavin Clark-Gartner maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and raises the price target from $295 to $300.